BSX Boston Scientific Corporation

MARLBOROUGH, Mass., Oct. 1, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast an investor update at the virtual 2020 Transcatheter Cardiovascular Therapeutics (TCT) on Thursday, October 15 from 1:00 – 2:00 p.m. EDT. Joe Fitzgerald, executive vice president and president, Interventional Cardiology; Michael Jaff, D.O., vice president and chief medical officer, clinical affairs, technology and innovation, Peripheral Interventions; Dr. Ian Meredith, AM, executive vice president and global chief medical officer; and Jeff Mirviss, executive vice president and president, Peripheral Interventions will provide a business update and answer questions from investors about the Boston Scientific cardiovascular portfolio.

On Wednesday, October 28, 2020 Boston Scientific will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2020. The call will begin at 8:00 a.m. EDT, hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the third quarter on October 28 prior to the conference call.

A live webcast and replay of the webcast for each event will be accessible at investors.bostonscientific.com. The replay will be available beginning approximately one hour following the completion of each event.

About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.  As a global medical technology leader for 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.

View original content to download multimedia:http://www.prnewswire.com/news-releases/boston-scientific-announces-transcatheter-cardiovascular-therapeutics-2020-investor-update-and-conference-call-discussing-third-quarter-2020-results-301143705.html

SOURCE Boston Scientific Corporation